8 Dermatology Headlines You Missed in June 2026

In the month of June 2026, the dermatology field saw a significant number of major developments in terms of new treatment data, US Food and Drug Administration (FDA) approvals, and conferences.

In additional to typical news coverage, HCPLive covered 3 notable dermatology conferences: the 2026 Revolutionizing Atopic Dermatitis (RAD) Conference, the SDPA 2026 Annual Summer Dermatology Conference, and Maui Derm NP+PA Summer 2026. Coverage of these meetings included a number of significant studies and informative on-site interviews.

From new data to conference coverage to FDA developments, the final month of 2026’s second quarter proved to be a substantial one in the skin health space. The following iteration of HCPLive’s Month in Review series highlights the top stories from June 2026:

FDA News in June 2026:

FDA Approves Roflumilast 0.3% Cream for PsO in Children 2-5 Years

Roflumilast cream 0.3% (Zoryve), by Arcutis Biotherapeutics, was approved in June for the treatment of pediatric patients as young as 2 years of age with plaque psoriasis. This move expands the topical phosphodiesterase 4 (PDE4) inhibitor's current indications in the psoriasis space, which had previously been limited to patients aged 6 and older. The drug is now the first and only topical PDE4 inhibitor indicated for psoriasis in patients under 6 years of age.

FDA Approves Risankizumab for Pediatric Plaque Psoriasis, Psoriatic Arthritis

AbbVie announced the risankizumab-rzaa (SKYRIZI) approval in June for children aged 6 years or older with moderate to severe plaque psoriasis. Such children must also be candidates for systemic therapy or phototherapy. In this announcement, risankizumab was also approved for those aged 6 years or older with active psoriatic arthritis (PsA). The approval also adds a 55-mg prefilled syringe designed to support weight-based dosing for those less than 40 kg.

FDA Adds Bemotrizinol as First New Sunscreen Ingredient in Decades

In another June FDA announcement, bemotrizinol was added as an active ingredient in its list of over-the-counter (OTC) sunscreen products for skin cancer protection. The decision by FDA officials marks the first addition of a new active ingredient to the OTC sunscreen monograph in decades. Bemotrizinol, approved in Europe and various other international markets, is an ingredient designed to provide broad-spectrum protection against the sun’s ultraviolet A (UVA) and ultraviolet B (UVB) radiation.

Top Podcasts in June 2026:

The Medical Sisterhood: The Strength Nobody Talks About, with Saakshi Khattri, MD

In the June episode of The Medical Sisterhood podcast, host Mona Shahriari, MD, associate clinical professor of dermatology at Yale University, spoke with Saakshi Khattri, MD, a triple board-certified physician in dermatology, rheumatology, and internal medicine. Khattri is also an associate professor at the Icahn School of Medicine at Mount Sinai and the director of Mount Sinai’s Dermatology/Rheumatology service. The topics of career contentment, reinvention, boundaries, and what success means for women in medicine were all highlighted.

Skin of Color Savvy: Patient Power—Voices Driving Change in Skin of Color Care

In June’s Skin of Color Savvy podcast, produced by HCPLive and hosted by Skin of Color Savvy (SOCS) leaders, a conversation was held by host Elizabeth A. Kiracofe, MD, a board-certified dermatologist and founder of Airia Comprehensive Dermatology. Avery LaChance, MD, MPH, of Brigham and Women’s Hospital, and Barry Gardner, a biologic coordinator and medical assistant with LARK Dermatology who is currently completing his path toward becoming a physician assistant, joined her to discuss advancing equitable dermatologic care for patients with skin of color and other topics.

ABCs in Dermatology: Updates in Atopic Dermatitis Live at RAD 2026

A live recording of ABCs in Dermatology was held by co-hosts Christopher Bunick, MD, PhD, and Lindsay Ackerman, MD, FAAD. The pair discussed the maturing interleukin-4 (IL-4)/interleukin-13 (IL-13) biologic landscape in atopic dermatitis. The talk was recorded live at the RAD 2026 meeting in Nashville, Tennessee. Tralokinumab (Adbry), dupilumab (Dupixent), and lebrikizumab (Ebglyss) were all highlighted.

Other Dermatology News:

Dupilumab Improves Growth, Skin, & Caregiver Burden Across Pediatric AD Spectrum

At the RAD 2026 Conference, a set of analyses from LIBERTY AD PEDS, LIBERTY AD PRESCHOOL, and the long-term PED-OLE extension study were presented demonstrating dupilumab’s improvement as far as growth attainment in school-age children. The drug was shown to provide rapid caregiver-reported relief of symptoms in both infants and toddlers. It was also was shown to result in sustained regional skin improvements for up to 3 years in children with atopic dermatitis.

Zasocitinib Bests Deucravacitinib on PsO Skin Clearance in Phase 3 Head-to-Head

Topline results announced in June by Takeda suggest zasocitinib, a once-daily oral tyrosine kinase 2 (TYK2) inhibitor, showed statistically superior rates of complete plaque psoriasis skin clearance versus deucravacitinib across all primary and key secondary endpoints. These data were the result of a phase 3 head-to-head trial in adults with moderate-to-severe disease known as the LATITUDE Atlas study.